Interpace Diagnostics Group, Inc. (NASDAQ:IDXG)‘s stock had its “buy” rating restated by Maxim Group in a report issued on Tuesday. They presently have a $5.00 price target on the business services provider’s stock. Maxim Group’s price objective points to a potential upside of 323.73% from the stock’s previous close.

Separately, ValuEngine upgraded Interpace Diagnostics Group from a “strong sell” rating to a “sell” rating in a research note on Monday, September 11th.

Interpace Diagnostics Group (NASDAQ IDXG) traded down $0.05 during trading on Tuesday, hitting $1.18. The company’s stock had a trading volume of 947,000 shares, compared to its average volume of 2,159,749. The company has a market cap of $33.02, a P/E ratio of 0.43 and a beta of 1.62. Interpace Diagnostics Group has a 1-year low of $0.70 and a 1-year high of $19.80.

COPYRIGHT VIOLATION NOTICE: “Interpace Diagnostics Group, Inc. (IDXG) Rating Reiterated by Maxim Group” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at

An institutional investor recently bought a new position in Interpace Diagnostics Group stock. Sabby Management LLC acquired a new stake in shares of Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) during the second quarter, according to its most recent disclosure with the SEC. The fund acquired 529,819 shares of the business services provider’s stock, valued at approximately $476,000. Sabby Management LLC owned approximately 2.39% of Interpace Diagnostics Group as of its most recent SEC filing. Institutional investors and hedge funds own 7.15% of the company’s stock.

Interpace Diagnostics Group Company Profile

Interpace Diagnostics Group, Inc, formerly PDI, Inc, is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management.

Receive News & Stock Ratings for Interpace Diagnostics Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group Inc. and related stocks with our FREE daily email newsletter.